Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295359 | 0.91 | CYP1A2 (0.59) | HTTLMNATDP1CYP1A2POLB | |
| SCHEMBL208938 | 0.83 | — | — | |
| SCHEMBL1197205 | 0.79 | CYP1A2 (0.52) | TDP1CYP1A2KMT2AALDH1A1 | |
| SCHEMBL2852512 | 0.79 | HTT (0.57) | HTTLMNATDP1CYP1A2KMT2A | |
| SCHEMBL2616307 | 0.79 | TDP1 (0.81) | HTTLMNATDP1CYP1A2KMT2A | |
| SCHEMBL4000585 | 0.78 | HTT (0.52) | HTTLMNATDP1CYP1A2KMT2A | |
| SCHEMBL22273305 | 0.78 | ALDH1A1 (0.67) | HTTLMNATDP1CYP1A2KMT2A | |
| SCHEMBL23199864 | 0.77 | HTT (0.55) | HTTLMNATDP1CYP1A2KMT2A | |
| SCHEMBL14534799 | 0.77 | HTT (0.55) | HTTLMNATDP1CYP1A2KMT2A | |
| SCHEMBL14376444 | 0.77 | TDP1 (0.56) | HTTLMNATDP1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | claimed |
| JP-2011524411-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | claimed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | claimed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8420684-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome, Huntington's Disease; hypotensive agents; sleeping/eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 4-Cyclopropylimino-5-(3,4-dihydro-2H-pyran-2-yl)-1-(3-imidazol-1-yl-propyl)-imidazolidin-2-one | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | HTT 1606/4885LMNA 4323/4885TDP1 3276/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | HTT 2099/4885LMNA 4828/4885TDP1 1858/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | HTT 3852/4885LMNA 1202/4885TDP1 2016/4885 |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | HTT 4085/4885LMNA 2421/4885TDP1 2762/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | HTT 4667/4885LMNA 3337/4885TDP1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.